The Life Science supply chain is strategic and of fundamental importance for the resilience and sustainability of our country, thanks to its capacity to ensure both health and socio-economic development. This public-private ecosystem, characterized by a high level of innovation and top-tier expertise, represents 13% of Lombardy’s GDP in terms of added value, with an increase of two percentage points over the past five years.
The Lombardy Life Science ecosystem, bolstered by a longstanding public-private collaboration and significant social impact, represents an unicum in Italy in terms of clinical results, research value, innovative care, and closeness to citizens’ needs. It encompasses 1/3 of Italy’s pharmaceutical and medtech supply chain and leads the digital transformation of healthcare in the country.
Milan Life Science Forum 2024 (9.30-13.00)
Building on these strengths, the 7th edition of the Milan Life Sciences Forum aims to foster dialogue between the public and private sectors, including businesses, science, and the nonprofit sector, to share and assess the current state of healthcare and establish a shared vision for the future of healthcare. The event will highlight the Life Sciences sector as a driving force for health, social, and strategic development, both for Lombardy and for Italy.
During the 2024 edition, the new report “The Importance of the Life Sciences Supply Chain in Lombardy: Benchmarking between Italian and European Regions” will be presented. Compiled biennially by Assolombarda’s Research Center – in collaboration with key industry associations: Cergas-Bocconi and the Lombardy Life Sciences Cluster – the report explores the economic impact and development trends within the Life Science supply chain.
Clinical Research Forum (14.00-16.30)
Thanks to the collaboration with Cluster lombardo scienze della vita, this year’s edition will continue in the afternoon with the 3rd edition of the Clinical Research Forum. This initiative will explore the current landscape and priorities within the field of clinical research to consolidate Lombardy’s and Italy’s competitiveness in attracting studies, trials, investments, and innovations to benefit the National Health System and its citizens.